CELG-RI
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$0.11
+0.00%Oct 29, 2026, 15:02 UTC
VEEVA SYSTEMS INC announced that executives from ASTRAZENECA PLC, BRISTOL MYERS SQUIBB CO, Grünenthal GmbH, NOVO NORDISK A S, Roche Holdings, Inc. and UCB SA are among those featured at Veeva Summit, which presents innovations in AI and data for an agent-based commercial model.
Source:Oct 29, 2026, 13:36 UTC
BRISTOL MYERS SQUIBB CO reported quarterly earnings of $1.35 per share, compared with $1.63 per share a year earlier.
Source:Oct 29, 2026, 11:00 UTC
BRISTOL MYERS SQUIBB CO raised the upper end of its 2026 revenue guidance to $50.25 billion from $50 billion.
Source:Oct 29, 2026, 10:59 UTC
BRISTOL MYERS SQUIBB CO reported third-quarter revenue of $13.07 billion, above expectations of $12.71 billion.
Oct 27, 2026, 02:27 UTC
Daiichi Sankyo shares fell sharply after BRISTOL MYERS SQUIBB CO and SystImmune announced positive clinical-trial results for izalontamab brengitecan, viewed as a potential competitor to Daiichi Sankyo’s Datroway.
Source:Oct 26, 2026, 07:30 UTC
The Phase 3 PANKU-Lung01 study reported that izalontamab brengitecan doubled median progression-free survival versus chemotherapy in previously treated patients with EGFR-mutated non-small cell lung cancer.
Source:Oct 25, 2026, 07:31 UTC
BRISTOL MYERS SQUIBB CO and BioNTech SE announced positive global Phase 2 data for pumitamig in advanced non-small cell lung cancer that progressed after immunotherapy combined with chemotherapy.
Oct 23, 2026, 22:46 UTC
BRISTOL MYERS SQUIBB CO shares closed at $61.48, down 2.41% from the previous close.
Source:Oct 23, 2026, 17:28 UTC
BRISTOL MYERS SQUIBB CO shares traded lower on Friday.
Source:Oct 23, 2026, 14:52 UTC
BRISTOL MYERS SQUIBB CO reported that a patient with multiple sclerosis died of septic pneumonia during a CAR-T study.
Oct 23, 2026, 14:30 UTC
BRISTOL MYERS SQUIBB CO presented Phase 1 Breakfree-2 study results for zolacabtagene autoleucel (BMS-986353) in patients with highly active relapsing and progressive multiple sclerosis.
Source:Oct 23, 2026, 13:01 UTC
Tempus AI, Inc. said BRISTOL MYERS SQUIBB CO will license its multimodal oncology data through 2031 to support the identification of biological and clinical insights.
Oct 23, 2026, 13:00 UTC
Pathos AI, Inc. announced multi-year strategic collaborations with BRISTOL MYERS SQUIBB CO and Tempus AI to build a curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions.
Oct 23, 2026, 13:00 UTC
Pathos AI, Inc. announced a partnership with BRISTOL MYERS SQUIBB CO that will initially focus on Alzheimer’s treatments.
Source:Oct 23, 2026, 13:00 UTC
BRISTOL MYERS SQUIBB CO announced that it leads Pathos AI, Inc.’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio.
Oct 22, 2026, 10:45 UTC
BioNTech SE and GILEAD SCIENCES, INC. announced a clinical trial collaboration and supply agreement to evaluate pumitamig with sacituzumab govitecan as first-line treatment for locally advanced or metastatic PD-L1-low or -negative triple-negative breast cancer.
Source:Oct 19, 2026, 17:30 UTC
BRISTOL MYERS SQUIBB CO reported 96% MICROSOFT CORP 365 Copilot adoption across its approximately 30,000-person workforce.
Source:Oct 19, 2026, 10:59 UTC
BRISTOL MYERS SQUIBB CO announced that it plans to showcase cancer modalities and its solid-tumor portfolio at ESMO 2026.
Source:Oct 17, 2026, 21:45 UTC
AbbVie Inc., BRISTOL MYERS SQUIBB CO and Boehringer Ingelheim moved to intervene in the lawsuit over the 340B rebate pilot.
Source:Oct 14, 2026, 22:45 UTC
The listed top gainers included Perrigo, up 3.77%; GILEAD SCIENCES, INC., up 3.8%; Kroger, up 3.87%; BRISTOL MYERS SQUIBB CO, up 4.61%; and UNITEDHEALTH GROUP INC, up 4.73%.
Source:Oct 13, 2026, 18:40 UTC
BRISTOL MYERS SQUIBB CO reported mixed Phase III trial results for admilparant in idiopathic pulmonary fibrosis and positive results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors.
Source:Oct 12, 2026, 22:46 UTC
BRISTOL MYERS SQUIBB CO shares closed at $57.60, down 2.58% from the previous close.
Source:Oct 12, 2026, 16:59 UTC
Contineum Therapeutics, Inc. shares plunged Monday after mixed Phase 3 results for a competing lung disease drug.
Source:Oct 12, 2026, 10:55 UTC
BRISTOL MYERS SQUIBB CO announced positive topline results from the interim Phase 3 ACTION-1 analysis of RYZ101 in patients with GEP-NETs.
Oct 12, 2026, 10:50 UTC
BRISTOL MYERS SQUIBB CO reported that its Phase III ALOFT-IPF trial of admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
Oct 12, 2026, 10:50 UTC
BRISTOL MYERS SQUIBB CO said a study met its primary endpoint.
Source:Oct 8, 2026, 22:00 UTC
The UK government will invest £33 million through the Dame Barbara Windsor Dementia Goals programme to support dementia research and clinical-trial recruitment.
Source:Oct 8, 2026, 22:00 UTC
The UK government will announce a £48 million partnership with healthcare companies and charities to accelerate dementia research and development.
Oct 8, 2026, 16:27 UTC
BRISTOL MYERS SQUIBB CO announced topline results from its Phase 3 EXCALIBER-RRMM study of Zenbexus, reporting a 51% reduction in blood cancer progression risk.
Source:Oct 8, 2026, 10:59 UTC
BRISTOL MYERS SQUIBB CO announced that ZENBEXUS (iberdomide) combined with daratumumab and dexamethasone demonstrated superior progression-free survival versus an unspecified comparator.
Source:Sep 21, 2026, 11:06 UTC
SystImmune, a wholly owned subsidiary of Sichuan Biokin Pharmaceutical, triggered the second $250 million near-term contingent payment under its global strategic collaboration with Bristol Myers Squibb for iza-bren (BL-B01D1) after the global Phase III IZABRIGHT-Lung02 trial reached a milestone.
Source:
Page 1Next →